Previously recorded as Biogen Hemophilia Inc. (to 2017)
78 patents currently held
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Mar 2027
Next term end
40
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2031 · Medium confidence
Also notable
Ends Jun 2028 · High confidence
Also notable
Ends Apr 2031 · High confidence
Also notable
Ends May 2035 · High confidence
Also notable
Ends Jan 2034 · High confidence
Also notable
Ends May 2033 · High confidence
Also notable
Ends Jan 2034 · High confidence
Also notable
Ends Apr 2035 · High confidence
Factor IX Polypeptides and Methods of Use Thereof
US 9,670,475
Cited by 84 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Immunoglobulin Chimeric Monomer-Dimer Hybrids
US 7,404,956
The most cited patent in this portfolio, cited by 238 later US patents, top 5% of utility patents granted in 2008 in our data. Protection runs to 2028.
Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
US 9,050,318
Cited by 107 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Factor VIII Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
US 10,010,622
Cited by 74 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Chimeric Factor VIII Polypeptides and Uses Thereof
US 11,370,827
Cited by 43 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Factor VIII Compositions and Methods of Making and Using Same
US 10,421,798
Cited by 44 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2033.
Factor VIII Complex with Xten and Von Willebrand Factor Protein, and Uses Thereof
US 10,138,291
Cited by 38 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Device Container
US 10,058,480
Cited by 23 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 9 to 27, 2026 · next Dec 9
- 3 fees due Feb 6 to 27, 2027 · next Feb 6
- 3 fees due Mar 5 to 24, 2027 · next Mar 5
- 1 fee due Apr 17, 2027The maintenance fee for Optimized Factor VIII Gene (US 11,787,851) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 2 fees due Jul 12 to 26, 2027 · next Jul 12
- 4 fees due Aug 4 to 25, 2027 · next Aug 4
- 1 fee due Sep 17, 2027The maintenance fee for Factor IX Polypeptide Formulations (US 10,588,949) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for On-Column Viral Inactivation Methods (US 10,611,794) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
- 1 fee due Nov 19, 2027The maintenance fee for Assays to Monitor Bleeding Disorders (US 10,656,167) comes due Nov 19, 2027. Unpaid by May 19, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
What they patent
The largest of its 40 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Factor IX Polypeptides and Methods of Use Thereof | 10 in force | to Sep 2031 |
| Device Container | 4 in force | to Nov 2035 |
| Factor IX Polypeptide Formulations | 3 in force | to Nov 2035 |
| On-Column Viral Inactivation Methods | 3 in force | to Nov 2035 |
| Optimized Factor VIII Gene | 3 in force | to Oct 2035 |
| Factor VIII Chimeric and Hybrid Polypeptides, and Methods of Use Thereof | 3 in force | to May 2035 |
| Factor VIII Polypeptide Formulations | 3 in force | to Jan 2035 |
| Methods of Reducing Immunogenicity Against Factor VIII in Individuals Undergoing Factor VIII Therapy | 3 in force | to Nov 2034 |
| Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof | 3 in force | to May 2031 |
| PC5 as a Factor IX Propeptide Processing Enzyme | 3 in force | to Sep 2027 |
| Optimized Factor IX Gene | 2 in force | to Nov 2038 |
| Factor VIII Chimeric Proteins and Uses Thereof | 2 in force | to Feb 2037 |
| Lyophilized Factor IX Formulations | 2 in force | to Nov 2036 |
| Assays to Monitor Bleeding Disorders | 2 in force | to Oct 2035 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,795,400 | PC5 as a Factor IX Propeptide Processing Enzyme In force · Medium confidence | In force | Medium confidence | |
| US 8,021,880 | PC5 as a Factor IX Propeptide Processing Enzyme In force · Medium confidence | In force | Medium confidence | |
| US 7,566,565 | PC5 as a Factor IX Propeptide Processing Enzyme In force · High confidence | In force | High confidence | |
| US 7,348,004 | Immunoglobulin Chimeric Monomer-Dimer Hybrids In force · High confidence | In force | High confidence | |
| US 7,404,956 | Immunoglobulin Chimeric Monomer-Dimer Hybrids In force · High confidence | In force | High confidence | |
| US D741,703 | Package In force · High confidence | In force | High confidence | |
| US D751,705 | Syringe In force · High confidence | In force | High confidence | |
| US 9,050,318 | Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,266,720 | Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,241,978 | Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 78: 5 patents in force now held by others · 17 patents ended · 34 applications pending · 51 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.